Article Versions Notes

Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda A, Garraus M, et al. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes. Cancers. 2023; 15(19):4837. https://doi.org/10.3390/cancers15194837

Muñoz, Juan Pablo, Cristina Larrosa, Saray Chamorro, Sara Perez-Jaume, Margarida Simao, Nazaret Sanchez-Sierra, Amalia Varo, Maite Gorostegui, Alicia Castañeda, Moira Garraus, and et al. 2023. "Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes" Cancers 15, no. 19: 4837. https://doi.org/10.3390/cancers15194837

Muñoz, J. P., Larrosa, C., Chamorro, S., Perez-Jaume, S., Simao, M., Sanchez-Sierra, N., Varo, A., Gorostegui, M., Castañeda, A., Garraus, M., Lopez-Miralles, S., & Mora, J. (2023). Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes. Cancers, 15(19), 4837. https://doi.org/10.3390/cancers15194837